Skip to main content

Anavex Life Sciences Corp.

AVXL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001314052

No open-market purchases or sales by Anavex Life Sciences Corp. insiders were filed in the last 90 days; 180 institutions reported holding it in 13F filings for Q2 2026, worth $95.8M in total; no superinvestor holds it.

Q1 2024 vs. Q4 2023

How the institutions holding Anavex Life Sciences Corp. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of AVXL: Q4 2023 compared with Q1 2024
MeasureQ4 2023Q1 2024Change
Holders153147−6
Shares25.9M31.9M+5.99M (+23.1%)
Value$240.8M$161.3M−$79.5M (−33.0%)

New holders (17)

Institutions that held Anavex Life Sciences Corp. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to AVXL in Q1 2024
InstitutionSharesValue% of portfolio
Sculptor Capital LP370,400$1.89M0.04%
Renaissance Technologies LLC79,900$407.0K0.00%
Sherbrooke Park Advisers LLC60,813$309.5K0.06%
Two Sigma Advisers, LP48,500$246.9K0.00%
Saxon Interests, Inc.26,699$135.9K0.06%
Gsa Capital Partners LLP20,895$106.0K0.01%
Fiduciary Alliance LLC13,275$66.6K0.01%
Quantbot Technologies LP12,000$61.1K0.00%
Mariner, LLC10,919$55.6K0.00%
Stratos Wealth Partners, LTD.10,802$55.0K0.00%
HSBC Holdings PLC10,407$52.9K0.00%
Pacer Advisors, Inc.3,120$15.9K0.00%
Fernwood Investment Management, LLC3,000$15.3K0.00%
CIBC Private Wealth Group, LLC2,000$10.0K0.00%
IAG Wealth Partners, LLC1,880$9.57K0.00%
Comerica Bank112$5700.00%
Nelson, Van Denburg & Campbell Wealth Management Group, LLC14$710.00%

Sold out (23)

Institutions that held Anavex Life Sciences Corp. at the end of Q4 2023 and filed for Q1 2024 without it.